An overview of the efficacy of resveratrol in the management of ischemic heart disease. (30th July 2015)

• Record Type: Journal Article
• Authors: Raj, Pema; Zieroth, Shelley; Netticadan, Thomas
• Other Names: Vang Ole guestEditor.; Pezzuto John M. guestEditor.
• Is Part Of: Annals of the New York Academy of Sciences. Volume 1348(2015)
• Page Start: 55
• Page End: 67
• Publication Date: 2015-07-30
• Subjects: resveratrol -- ischemic heart disease -- preclinical and clinical trial studies; Medical sciences -- Periodicals; Medicine -- Periodicals; Science -- Periodicals; 610
• DOI: 10.1111/nyas.12828
• Languages: English
• ISSNs: 0077-8923

Abstract

Abstract : Ischemic heart disease is a leading cause of cardiac dysfunction and subsequent morbidity and mortality around the world. New therapies are required to complement or enhance the existing treatment regimen for the management of ischemic heart disease–related clinical complications. In this regard, compounds derived from natural sources have recently gained attention for their cardioprotective properties. In particular, the potential of food‐derived compounds that exhibit medicinal properties (termed nutraceuticals ) appears promising, an example being the plant polyphenol resveratrol. In the past two decades, many preclinical and a few pilot clinical studies have shown that resveratrol is beneficial in protecting against cardiovascular disease. In this short review, we will discuss current evidence on the efficacy of resveratrol in preventing or reversing deleterious effects on the heart in the setting of ischemic heart disease.